Although cardiac cell therapy has been intensely studied, the high expectations are still an unmet goal. A study now characterizes the translational potential and mode of action of human ventricular progenitors (HVPs) derived from embryonic stem cells, as a source for cardiac cell therapy.
This is a preview of subscription content, log in via an institution to check access.
References
Menasché, P. et al. Lancet 357, 279–280 (2001).
Nguyen, P. K., Rhee, J. W. & Wu, J. C. JAMA Cardiol. 1, 831–841 (2016).
Nat. Biotechnol. 35, 291 (2017).
Madonna, R. et al. Eur. Heart J. 37, 1789–1798 (2016).
Cai, C. L. & Molkentin, J. D. Circ. Res. 120, 400–406 (2017).
Zwetsloot, P. P. et al. Circ. Res. 118, 1223–1232 (2016).
Vagnozzi, R. J. et al. Nature 577, 405–409 (2020).
Foo, K. S. et al. Mol. Ther. 26, 1644–1659 (2018).
Poch, C. M. et al. Nat. Cell Biol. https://doi.org/10.1038/s41556-022-00899-8 (2022).
Farbehi, N. et al. eLife 8, e43882 (2019).
Molenaar, B. & van Rooij, E. Circ. Res. 123, 1033–1035 (2018).
Chong, J. J. et al. Nature 510, 273–277 (2014).
Shiba, Y. et al. Nature 538, 388–391 (2016).
Liu, Y. W. et al. Nat. Biotechnol. 36, 597–605 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Timmer, L.T., van Rooij, E. Defining the pathways of heart regeneration. Nat Cell Biol 24, 606–607 (2022). https://doi.org/10.1038/s41556-022-00914-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41556-022-00914-y
- Springer Nature Limited